Expanding Structure-Activity Relationships of Human Urotensin II Peptide Analogues: A Proposed Key Role of the N-Terminal Region for Novel Urotensin II Receptor Modulators

被引:0
|
作者
Merlino, Francesco [1 ,2 ]
Secondo, Agnese [3 ]
Mitidieri, Emma [1 ]
Sorrentino, Raffaella [1 ]
Bellavita, Rosa [1 ]
Grasso, Nicola [1 ]
Chatenet, David [4 ]
Pannaccione, Anna [3 ]
Grieco, Paolo [1 ,2 ]
Bianca, Roberta d'Emmanuele di Villa [1 ]
Carotenuto, Alfonso [1 ,2 ]
机构
[1] Univ Naples Federico II, Sch Med & Surg, Dept Pharm, I-80131 Naples, Italy
[2] Univ Naples Federico II, Ctr Interuniv Ric Peptidi Bioattivi Carlo Pedone C, I-80134 Naples, Italy
[3] Univ Naples Federico II, Sch Med & Surg, Dept Neurosci Reprod & Dent Sci, Div Pharmacol, I-80131 Naples, Italy
[4] Univ Quebec, Inst Natl Rech Sci INRS, Ctr Armand Frappier Sante Biotechnol, Quebec City, PQ H7V 1B7, Canada
关键词
ANTAGONIST PALOSURAN; URANTIDE; BINDING; P5U; EXPRESSION; DISCOVERY; IMPROVES; LIGANDS; INSIGHT; CELLS;
D O I
10.1021/acs.jmedchem.4c00688
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
While the urotensinergic system plays a role in influencing various pathologies, its potential remains untapped because of the absence of therapeutically effective urotensin II receptor (UTR) modulators. Herein, we developed analogues of human urotensin II (h U-II) peptide in which, along with well-known antagonist-oriented modifications, the Glu1 residue was subjected to single-point mutations. The generated library was tested by a calcium mobilization assay and ex vivo experiments, also in competition with selected ligands. Interestingly, many derivatives showed noncompetitive modulation that was rationalized by the lateral allostery concept applied to a G protein-coupled receptor (GPCR) multimeric model. UPG-108 showed an unprecedented ability to double the efficacy of h U-II, while UPG-109 and UPG-111 turned out to be negative allosteric modulators of UTR. Overall, our investigation will serve to explore and highlight the expanding possibilities of modulating the UTR system through N-terminally modified h U-II analogues and, furthermore, will aim to elucidate the intricate nature of such a GPCR system.
引用
收藏
页码:13879 / 13890
页数:12
相关论文
共 42 条
  • [31] Elucidation of Structure-Activity Relationships in Indolobenzazepine-Derived Ligands and Their Copper(II) Complexes: the Role of Key Structural Components and Insight into the Mechanism of Action
    Kuznetcova, Irina
    Bacher, Felix
    Alfadul, Samah Mutasim
    Tham, Max Jing Rui
    Ang, Wee Han
    Babak, Maria V.
    Rapta, Peter
    Arion, Vladimir B.
    INORGANIC CHEMISTRY, 2022, 61 (26) : 10167 - 10181
  • [32] Structure-Activity Relationships of FMRF-NH2 Peptides Demonstrate A Role for the Conserved C Terminus and Unique N-Terminal Extension in Modulating Cardiac Contractility
    Maynard, Benjamin F.
    Bass, Chloe
    Katanski, Chris
    Thakur, Kiran
    Manoogian, Beth
    Leander, Megan
    Nichols, Ruthann
    PLOS ONE, 2013, 8 (09):
  • [33] A novel amino acid substitution of integrin αIIb in Glanzmann thrombasthenia confirms that the N-terminal region of the receptor plays a role in maintaining β-propeller structure
    Pillois, Xavier
    Fiore, Mathieu
    Heilig, Roland
    Pico, Marta
    Nurden, Alan T.
    PLATELETS, 2013, 24 (01) : 77 - 80
  • [34] QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP ANALYSIS OF SERIES OF SUBSTITUTED PIPERIDIN-2-ONE BIPHENYL TETRAZOLES ANALOGUES AS NOVEL ANGIOTENSIN II RECEPTOR ANTAGONISTS
    Sharma, M. C.
    Kohli, D. V.
    OXIDATION COMMUNICATIONS, 2013, 36 (01): : 176 - 189
  • [35] Synthetic studies on selective adenosine A2A receptor antagonists. Part II: Synthesis and structure-activity relationships of novel benzofuran derivatives
    Saku, Osamu
    Saki, Mayumi
    Kurokawa, Masako
    Ikeda, Ken
    Uchida, Shin-ichi
    Takizawa, Takuya
    Uesaka, Noriaki
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (12) : 3768 - 3771
  • [36] Structure-activity relationships of the N-terminus of calcitonin gene-related peptide: key roles of alanine-5 and threonine-6 in receptor activation
    Hay, Debbie L.
    Harris, Paul W. R.
    Kowalczyk, Renata
    Brimble, Margaret A.
    Rathbone, Dan L.
    Barwell, James
    Conner, Alex C.
    Poyner, David R.
    BRITISH JOURNAL OF PHARMACOLOGY, 2014, 171 (02) : 415 - 426
  • [37] Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide
    Spicer, JA
    Gamage, SA
    Atwell, GJ
    Finlay, GJ
    Baguley, BC
    Denny, WA
    JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (12) : 1919 - 1929
  • [38] Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1
    Green, BD
    Gault, VA
    Irwin, N
    Mooney, MH
    Bailey, CJ
    Harriott, P
    Greer, B
    Flatt, PR
    OHarte, FPM
    BIOLOGICAL CHEMISTRY, 2003, 384 (12) : 1543 - 1551
  • [39] Analysis of structure-activity relationships for the 'B-region' of N-(3-acyloxy-2-benzylpropyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea analogues as vanilloid receptor antagonists:: discovery of an N-hydroxythiourea analogue with potent analgesic activity
    Lee, J
    Kang, SU
    Choi, HK
    Lee, J
    Lim, JO
    Kil, MJ
    Jin, MK
    Kim, KP
    Sung, JH
    Chung, SJ
    Ha, HJ
    Kim, YH
    Pearce, LV
    Tran, R
    Lundberg, DJ
    Wang, Y
    Toth, A
    Blumberg, PM
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (09) : 2291 - 2297
  • [40] Structure-activity relationships within the N-terminal short consensus repeats (SCR) of human CR1 (C3b/C4b receptor, CD35): SCR 3 plays a critical role in inhibition of the classical and alternative pathways of complement activation
    Mossakowska, D
    Dodd, I
    Pindar, W
    Smith, RAG
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1999, 29 (06) : 1955 - 1965